Skip to main content
. 2014 Sep 3;112(11):2697–2706. doi: 10.1152/jn.00316.2014

Fig. 4.

Fig. 4.

The purinergic receptor antagonist PPADS failed to block the effect of QX-314 at TRPV1− afferents. Application of QX-314 in the presence of 20 μM PPADS does not prevent the increase in latency (A) or the failures (C) of ST-EPSCs in this representative cell. B: summary of the QX-314 effects on latency. D: QX-314 increased the failure rate of EPSC1. All asterisks are for P ≤ 0.05.